Key result
The global burden of ischemic heart disease has increased by 29% to 29 million disability-adjusted life years, highlighting the need for cost-effective acute management and secondary prevention.
This chapter reviews the growing global burden of ischemic heart disease and outlines cost-effective strategies for acute management and secondary prevention, particularly in LMICs.
Answers are grounded in this paper and cite their sources.
Mounting IHD burden calls for cost-effective strategies; leaves open scalable implementation in LMICs.
Cardiovascular disease (CVD) is the single most important cause of death worldwide; in 2010, it resulted in 16 million deaths and the loss of 293 million disability-adjusted life years (DALYs) (Lozano and others 2012; Murray and others 2012). CVD involves conditions that affect the vasculature that supplies the heart, brain, and other vital organs (Roth and others 2015). Of all of the causes of CVD, ischemic heart disease (IHD) remains the major contributor to mortality and morbidity. IHD results from delivery of insufficient oxygen to meet the demands of the heart and largely manifests as angina, acute myocardial infarction, and ischemic heart failure.Over the past two decades, although age-standardized IHD mortality has decreased in most regions, the global burden of IHD has increased by 29 percent to 29 million DALYs, in part because of a larger aging population and overall population growth (Lozano and others 2012; Moran, Forouzanfar, and others 2014a; Murray and others 2012). IHD is projected to be a major cause of death in 2030, along with unipolar depressive disorders and human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) (Mathers and Loncar 2006).This chapter reviews the global burden of IHD, with a focus on low- and middle-income countries (LMICs). We review the cost-effective management of acute IHD and subsequent secondary prevention; primary prevention is discussed in chapter 22 (Jeemon and others 2017). The chapter concludes with a discussion of the challenges that IHD poses to the global community and of solutions that may help reduce attendant mortality and morbidity.
No takes yet. Share an insight, caveat, or question.
Dugani et al. (2017) conducted a review in Ischemic Heart Disease. Cost-effective acute management and secondary prevention was evaluated. The global burden of ischemic heart disease has increased by 29% to 29 million disability-adjusted life years, highlighting the need for cost-effective acute management and secondary prevention.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: